CME Satellite Symposia

Monday, December 5 | 6:30 AM - 7:30 AM

Selective Sphingosine 1-Phosphate Receptor Modulators and Other Patient-Care Opportunities in IBD

This session is supported by an independent educational grant from Bristol Myers Squibb.

Learning Objectives:

  • Describe the mechanism of action of S1P receptor modulators
  • Evaluate efficacy and safety data associated with current and emerging S1P receptor modulator drugs
  • Implement key patient-care strategies, including shared decision-making, into clinical practice for IBD

Monday, December 5 | 1:00 PM - 2:00 PM

Evolving Strategies for the Management of Recurrent C. difficile Infection in Patients with IBD

This session is supported by an independent educational grant from Seres Therapeutics, Inc. & Aimmune Therapeutics.

Learning Objectives:

  • Describe the epidemiology, burden, and management challenges associated with initial and recurrent CDIs in patients with IBD
  • Assess the efficacy and safety data associated with current and emerging non-antibiotic therapies for the management and prevention of recurrent CDI
  • Implement appropriate, evidence-based strategies for the management and prevention of recurrent CDIs in patients with IBD

 

The Current and Potential Role of IL-12/23 and IL-23 Inhibition in Data-Driven Management of IBD

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Learning Objectives:

  • Describe the pathophysiologic rationale for the development of IL-12/23 and IL-23 inhibitors for IBD
  • Assess the safety and efficacy data associated with current and emerging IL-12/23 and IL-23 inhibitors
  • Evaluate and utilize data-driven treatment algorithms for IBD management

Tuesday, December 6 | 4:20 PM - 5:20 PM

Evolving Considerations for Therapeutic Drug Monitoring in IBD: Who, What, Why, When, and How?

This session is supported by an independent educational grant from Prometheus Laboratories Inc.

Learning Objectives:

  • Assess the utility of TDM in evaluating serum biologic drug concentrations in patients struggling with PNR and secondary LOR to anti-TNF therapy
  • Explain the differences between reactive and proactive TDM, including considerations for when to initiate each
  • Evaluate currently available assays for precision-guided dosing and TDM in the management of IBD

Wednesday, December 7 | 12:30 PM - 1:30 PM

Identifying and Managing Bowel Urgency in Ulcerative Colitis

This session is supported by an independent educational grant from Eli Lilly and Company.

Learning Objectives:

  • Describe the burden and impact of bowel urgency in patients with UC
  • Implement strategies to improve the recognition and assessment of bowel urgency in patients with UC
  • Evaluate the most recent clinical data associated with emerging therapies that may address the symptoms of bowel urgency

 

Intravenous Iron in Inflammatory Bowel Disease: Closing Outcomes Chasms through the Effective Management of Iron Deficiency Anemia

This symposium is supported by an independent educational grant from Creative Educational Concepts; Supported by an independent educational grant from American Regent, Inc.

Learning Objectives:

  • Discuss the basic principles of iron metabolism and absorption, including the practical distinctions between functional and absolute iron deficiency, with a focus on how these principles apply to IDA treatment in IBD.
  • Evaluate the role of iron deficiency as an etiology for anemia in IBD.
  • Recognize the prevalence of comorbid IBD and IDA and describe the substantial impact of anemia on IBD patient-reported quality-of-life metrics and clinical outcomes.
  • Review the essential utility of serum ferritin, transferrin saturation (TSAT), and C-reactive protein as diagnostic laboratory indices, alongside hemoglobin, for IDA in IBD.
  • Examine the pathophysiologic principles of how inflammation and hepcidin affect iron availability and utilization, especially in an intrinsically hyperinflammatory condition like IBD, and the resultant rationale for preferential treatment with IV iron vs oral iron.
  • Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
  • Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in IBD.
  • Compare and contrast FDA-approved IV iron products, including new indications and dosing regimens.
  • Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
  • Design innovative, evidence-supported clinical tools that can interface with institutional EHRs, such as diagnostic algorithms, digitalized checklists to promote IBD GDMT, and Ganzoni’s formula to determine iron repletion dosages.